Table 3.

Outcomes: chemotherapy received, dose reduction and delays.

Variable	All patients, N = 142			Adjuvant setting, N = 77			Palliative setting, N = 44
	I N = 71, n (%)	C N = 71, n (%)	P	I N = 40, n (%)	C N = 37, n (%)	P	I N = 22, n (%)	C N = 22, n (%)	P
Completed planned treatment (primary endpoint) initial dose in all planned cycles	32 (45)	20 (28)	0.0366	20 (50)	8 (22)	0.0097	7 (32)	8 (36)	0.751
Reduced start dose	44 (62)	41 (58)	0.732	23 (58)	16 (43)	0.211	15 (68)	19 (86)	0.150
Reduction of chemotherapy during treatment	20 (28)	32 (45)	0.037	10 (25)	21 (57)	0.005	8 (36)	7 (32)	0.750
Treatment delay	25 (35)	24 (34)	0.860	8 (20)	15 (41)	0.049	13 (59)	6 (27)	0.033
Received initial dose in all given cycles	46 (65)	30 (42)	0.007	25 (63)	11 (30)	0.004	14 (64)	12 (59)	0.540
Received all planned cycles	41 (58)	39 (55)	0.735	26 (65)	21 (57)	0.459	10 (45)	11 (50)	0.763
	Median (range)		P	Median (range)		P	Median (range)		P
Dose intensity: capecitabine/5-FU (%)	84 (35–117)	89 (11–117)	0.724	89 (67–117)	95 (47–117)	0.662	93 (35–112)	75 (11–100)	0.343
Dose intensity: oxaliplatin (%)	75 (22–169)	87 (31–130)	0.134	80 (22–169)	87 (31–92)	0.304	78 (49–103)	76 (76–76)	1.000
Dose intensity: irinotecan (%)	65 (27–116)	66 (4–110)	0.883	–	–	–	67 (27–116)	63 (4–104)	0.240
% of planned cycles received capecitabine/5-FU	100 (8–100)	100 (8–100)	NA	100 (8–100)	100 (8–100)	NA	89 (13–100)	92 (13–100)	0.763
% of planned cycles received oxaliplatin	58 (8–100)	63 (8–100)	0.825	50 (8–100)	50 (8–100)	0.888	89 (25–100)	100 (100–100)	1.000
% of planned cycles received irinotecan	93 (60–100)	96 (25–100)	0.751	–	–	–	91 (60–100)	90 (25–100)	1.000
Duration of chemotherapy (weeks)	22.1 (0.3–43)	20.1 (0.1–53)	0.905	22.6 (0.3–27)	22.4 (0.3–29)	0.855	17.2 (0.3–43)	21.6 (0.1–52)	0.675

I intervention, C control, 5-FU 5-flourouracil.

Bold values indicate significant differences between the intervention and control group.